Where is Arkema's head office located?
Arkema S.A., a global leader in specialty chemicals and advanced materials, is headquartered in Colombes, France. Located in the Paris metropolitan region, the corporate head office functions as the central executive and administrative hub for the company's diverse international industrial divisions. From this location, Arkema directs its research, innovation, and global production strategy, focusing on high-performance materials such as adhesives, advanced polymers, and specialty chemicals. The Colombes site houses the executive leadership team responsible for overseeing the company's extensive network of manufacturing plants, R&D centers, and distribution hubs across Europe, the Americas, and Asia, providing essential chemical solutions to industries including transportation, electronics, and construction, all managed from its prominent French corporate headquarters.
Related FAQs
Arkema S.A. shares trade on Euronext Paris at valuations reflecting conditions in the global specialty chemicals and advanced materials sectors.
Arkema structures its dividend policy as a core component of its overall shareholder return framework, aiming to provide regular, predictable, and progressively increasing financial rewards to investors.
Arkema, a prominent global specialty chemicals and advanced materials company headquartered near Paris, France, was created in 2004 through a massive corporate restructuring of the chemical branch of the French energy conglomerate Total.
Armstrong Bank has served its communities as a family-owned financial institution for over a century, tracing its operational history back to its founding in 1909 in Muskogee County, Oklahoma.
The corporate brand name Arkema is a carefully crafted portmanteau and trade name established when major chemical assets were reorganized, blending linguistic elements that evoke chemistry, advanced materials, and enterprise strength.
Assessing whether Arkema shares are undervalued depends on valuation modeling comparing current market trading prices against estimated future cash flows and peer industry multiples.
Determining whether Arkema represents a favorable purchase or an asset to sell involves analyzing consensus brokerage opinions, which typically cluster around a neutral hold to moderate buy range.
Arkema operates in the global specialty chemicals and advanced materials sector, competing against major multinational chemical enterprises. Its primary international competitors include companies such as BASF SE, Dow Inc.
Arkema sells a broad portfolio of advanced specialty chemicals, high-performance engineering polymers, industrial coating resins, adhesives, and fluorochemical products to corporate clients across the globe.
Equity research analysts project stable, multi-year growth prospects for Arkema, driven by its strategic transformation into a pure-play specialty materials manufacturer.
Equity research analysts covering Arkema S.A.
Arkema S.A. is a major French multinational specialty chemicals and advanced materials manufacturer.
Arkema operates as a fully public corporate entity, listed and traded prominently on Euronext Paris under the ticker symbol AKE.
Market strategists frequently point to sectors experiencing temporary regulatory headwinds, cyclical downturns, or shifts in institutional investor sentiment—such as traditional regional banking, selective biotechnology, or certain energy sub-sectors...
No, BPCL and Indian Oil are completely separate, independent public sector undertakings (PSUs) owned by the Government of India, operating as fierce competitors in the nation's downstream petroleum refining and fuel marketing sector.
Equity research analysts tracking Arkema stock generally assign mixed to moderately positive consensus ratings, balancing its long-term positioning in specialty materials and eco-friendly battery components against cyclical industrial demand.
Arkema is not a United States enterprise, maintaining its corporate headquarters, legal domicile, and primary operational roots in Colombes, France.
Arkema is a global specialty chemicals and advanced materials manufacturer producing a diverse portfolio of high-performance solutions for industrial applications.
Ascendis Pharma A/S, a biopharmaceutical company focused on developing a pipeline of innovative therapies utilizing its proprietary TransCon technology platform, maintains a specialized global workforce of approximately 1,500 employees.